Molecular brace traps two cancer-driving proteins to suppress prostate cancer growth in preclinical tests

Medical Xpress - latest medical and health news stories ·
Health & Medicine United Kingdom

Many modern cancer drugs typically target a specific protein or signaling pathway to treat tumors. Now, researchers at the University of Michigan Health Rogel Cancer Center are taking a new approach by throwing a molecular wrench into the machinery driving prostate cancer. In preclinical studies, this new approach demonstrated greater antitumor activity while sparing normal cells.

Read original article on Medical Xpress - latest medical and health news stories →

Related news